Analysts are on the Bearish side about Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) this week.

January 22, 2018 - By Marie Mckinney

 Analysts are on the Bearish side about Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) this week.
Investors sentiment decreased to 2 in Q3 2017. Its down 0.22, from 2.22 in 2017Q2. It worsened, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported.
Citadel Advsrs Lc owns 10,137 shares. Consonance Capital Mgmt L P reported 369,298 shares. Moreover, Royal Bancorporation Of Canada has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 171,487 shares. Northern, Illinois-based fund reported 811,513 shares. Deutsche Fincl Bank Ag owns 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 446,407 shares. 15,261 were reported by Tower Cap Ltd (Trc). 500 were reported by Cwm Llc. Blackrock has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). 30,372 were reported by Virtu Ltd Liability Company. Wells Fargo & Mn reported 29,128 shares or 0% of all its holdings. Kennedy Mngmt Inc stated it has 0.04% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Ameritas Partners has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Bank & Trust Of America De stated it has 7,132 shares. State Board Of Administration Of Florida Retirement Systems invested in 20,000 shares. Broadfin Ltd Liability has invested 2.57% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. Roth Capital maintained the shares of CPRX in report on Thursday, August 10 with “Buy” rating. The company was maintained on Wednesday, August 30 by Roth Capital. The firm has “Buy” rating by H.C. Wainwright given on Friday, November 10. The stock has “Buy” rating by SunTrust on Monday, November 27. The company was upgraded on Wednesday, October 5 by Piper Jaffray. The company was maintained on Tuesday, October 31 by SunTrust. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 11. PiperJaffray upgraded Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on Wednesday, October 5 to “Overweight” rating. The stock has “Buy” rating by SunTrust on Friday, September 1. The stock has “Buy” rating by Piper Jaffray on Monday, August 7. Below is a list of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) latest ratings and price target changes.

01/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $8.0 Maintain
27/11/2017 Broker: SunTrust Rating: Buy New Target: $6.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
01/11/2017 Broker: Roth Capital Rating: Buy New Target: $4.75 Maintain
31/10/2017 Broker: SunTrust Rating: Buy New Target: $5.0 Maintain
01/09/2017 Broker: SunTrust Rating: Buy New Target: $5.0 Maintain
30/08/2017 Broker: Roth Capital Rating: Buy New Target: $4.75 Maintain
11/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0000 Maintain
10/08/2017 Broker: Roth Capital Rating: Buy New Target: $4.7500 Maintain
07/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $6.0000 Maintain

The stock decreased 2.00% or $0.08 during the last trading session, reaching $3.67. About 174,060 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since January 22, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $376.59 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

More recent Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news were published by: Prnewswire.com which released: “Generic Drugs Stocks’ Research Reports Released on Catalyst Pharma, Flexion …” on January 09, 2018. Also Bizjournals.com published the news titled: “These companies top the list of South Florida’s best-performing stocks” on January 08, 2018. Zacks.com‘s news article titled: “What Drives Catalyst Pharmaceuticals Above 250% This Year?” with publication date: December 28, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: